To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Novo Nordisk's semaglutide for diabetes

FDA approved subcutaneous Ozempic semaglutide from Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) as an adjunct to diet and exercise to improve glycemic control in adults

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE